Loading...
Loading...
KURA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 36.6M |
| Operating I/L | -36.8M |
| Other Income/Expense | 2.5M |
| Interest Income | 2.9M |
| Pretax | -34.1M |
| Income Tax Expense | -3.1M |
| Net Income/Loss | -31.0M |
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company specializing in the development of small molecule product candidates for the treatment of cancer. Its lead products include ziftomenib, targeting genetically defined subsets of acute leukemias, and tipifarnib, in Phase II trials for solid tumors and hematologic indications. The company generates revenue through the development and potential commercialization of these innovative cancer treatments. Additionally, Kura Oncology has a clinical collaboration with Novartis to evaluate combination therapies for head and neck squamous cell carcinoma. With a focus on advancing cancer therapies, the company aims to drive growth and create value for patients and shareholders.
